{"disease":{"id":"oligometastatic-prostate-cancer","name":"oligometastatic prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05352178","title":"Metastasis-directed Therapy for Oligorecurrent Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":873,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT04115007","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05939414","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07015138","title":"Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07490210","title":"Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05053152","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":194,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05717660","title":"APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Careggi","has_results":false},{"nct_id":"NCT04610372","title":"5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03940235","title":"Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT06674863","title":"Addressing Health Literacy With a Tailored Survivorship Care Plan","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04992026","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06972511","title":"Maximal Tumor Eradication for Oligometastatic Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06205316","title":"SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06060652","title":"Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)","phase":"","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT05496959","title":"177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":93,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04190446","title":"A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07237399","title":"Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT06389786","title":"Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06387056","title":"Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT03298087","title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT06978296","title":"HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT04585932","title":"Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03301701","title":"Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Dr. Patrick Cheung","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}